GAB1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL282521	1.00	5/20
SCHEMBL282664	1.00	5/20
SCHEMBL282905	1.00	5/20
SCHEMBL283045	1.00	5/20
SCHEMBL287001	0.78	5/20
SCHEMBL288913	0.78	5/20
SCHEMBL282734	0.73	5/20
SCHEMBL283819	0.73	5/20
SCHEMBL282715	0.72	5/20
SCHEMBL11891689	0.72	5/20
SCHEMBL283691	0.70	5/20
SCHEMBL284048	0.69	5/20
SCHEMBL11891710	0.62	5/20
SCHEMBL3256711	0.56	5/20
SCHEMBL7144491	0.53	5/20
SCHEMBL282765	0.51	5/20
SCHEMBL11398588	0.47	5/20
SCHEMBL1413996	0.75	4/20
SCHEMBL5831475	0.67	4/20
SCHEMBL5830619	0.63	4/20

Clinical trials — most relevant to GAB1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion	PHASE4	RECRUITING
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD	PHASE3	COMPLETED
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML	PHASE2	RECRUITING
Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS	PHASE1/PHASE2	WITHDRAWN
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer	PHASE2	COMPLETED
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Selective Treatment According to Molecular Subtype of Prostate Cancer	PHASE2	UNKNOWN
Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia	PHASE1	COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE	PHASE1	RECRUITING
A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors	PHASE1	RECRUITING
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
The Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) on Working Memory	nan	COMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC	nan	UNKNOWN
Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia	nan	RECRUITING
STXBP1 and SYNGAP1 Related Disorders Natural History Study	nan	RECRUITING
Immune Cell Response to Stimuli	nan	RECRUITING
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation	nan	UNKNOWN
Clinical and Genetic Study of Autism Spectrum Disorder	nan	COMPLETED
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure	nan	UNKNOWN
Value of MicroRNA30a in Philadelphia Positive Leukemic Patients	nan	UNKNOWN
Genetics of the Early and Late Response to Allergen Challenge	nan	COMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a GAB1 binder may also engage these)

Protein	Name	Similarity
A6QLU3	—	1.000	A6QLU3 →
Q99PF6	—	1.000	Q99PF6 →
Q9QYY0	—	1.000	Q9QYY0 →
Q9Z1S8	—	1.000	Q9Z1S8 →
Q9UQC2	—	0.999	Q9UQC2 →
Q9EQH1	—	0.998	Q9EQH1 →
Q8C180	—	0.993	Q8C180 →
P84770	—	0.993	P84770 →
Q8BSM5	—	0.989	Q8BSM5 →
FRS2	Fibroblast growth factor receptor substrate 2	0.988	landscape →
Q91615	—	0.985	Q91615 →
Q9QUN3	—	0.983	Q9QUN3 →
P35569	—	0.983	P35569 →
Q8WV28	—	0.982	Q8WV28 →
Q06649	—	0.982	Q06649 →
Q4KM52	—	0.981	Q4KM52 →
Q8WWW8	—	0.980	Q8WWW8 →
Q5RJW5	—	0.980	Q5RJW5 →
Q62415	—	0.980	Q62415 →
Q28224	—	0.980	Q28224 →
Q8TEW8	—	0.979	Q8TEW8 →
Q3TTA7	—	0.978	Q3TTA7 →
Q9DF49	—	0.978	Q9DF49 →
Q9YGC1	—	0.978	Q9YGC1 →
Q8BM65	—	0.978	Q8BM65 →
Q8K4S7	—	0.978	Q8K4S7 →
P35570	—	0.977	P35570 →
IRS1	Insulin receptor substrate 1	0.977	landscape →
Q9P242	—	0.977	Q9P242 →
Q9HAU0	—	0.976	Q9HAU0 →